The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer. READ MORE

News

A recent survey found that approximately 33% of patients with breast cancer forego their physician-recommended adjuvant therapies due to distrust in medical institutions and insurers.

READ MORE

By Marilynn Larkin

NEW YORK (Reuters Health) – In women with breast cancer, zoledronic acid taken every three months is more cost-effective for reducing the risk of skeletal-related events than monthly zoledronic acid or monthly denosumab, researchers say.

READ MORE

Patients with breast cancer who take opioids to manage their pain are less likely to adhere to adjuvant therapy, resulting in a higher risk of death.

READ MORE